drugset / Trial / NCT04515706
Iguratimod in Systemic Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of iguratimod in adult subjects with diffuse cutaneous systemic sclerosis.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2023-01-31
- Completion
- 2024-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iguratimod | Small molecule | 25 unknown | — |